| • | | Amendment No. 1 to Amended and Restated Intercreditor Agreement, dated as of December 11, 2019 (the “A&R Intercreditor Amendment”), by and between the ABL Agent, the Term Agent (as defined in the A&R Intercreditor Amendment), and the ABL Lenders and Term Lenders (as defined in the A&R Intercreditor Amendment) party thereto, as acknowledged and consented to by each Loan Party (as defined in the A&R Intercreditor Amendment and including the Company). |
The foregoing descriptions of the ABL Amendment, the Intercreditor Amendment, and the A&R Intercreditor Amendment are summaries only and are qualified in their entirety by reference to the complete text of (i) the ABL Amendment, attached hereto as Exhibit 10.1, (ii) the Intercreditor Amendment, attached hereto as Exhibit 10.2, and (iii) the A&R Intercreditor Amendment, attached hereto as Exhibit 10.3, each incorporated by reference into this Item 1.01.
Warrant Agreement
On the Closing Date and in connection with the ABL Amendment, the Company entered into that certain Warrant Agreement (the “Warrant Agreement”), by and between the Company and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent. The Warrant Agreement provides that the Company shall issue, from time to time on and after the Closing Date, Series F warrants (the “Closing Date Warrants”) exercisable for up to 10% of the issued and outstanding shares (the “Closing Date Warrant Shares”) of Common Stock, on a fully diluted basis as of the Closing Date (or 2,040,430 shares of Common Stock), at an initial exercise price of $.0001 per share, and, immediately prior to the funding of the Fifth Amendment Additional Advance, Series F warrants (the “Additional Warrants” and collectively with the Closing Date Warrants, the “Series F Warrants”) to purchase up to 10% of the issued and outstanding shares (the “Additional Warrant Shares” and together with the Closing Date Warrant Shares, the “Warrant Shares”) of Common Stock, on a fully diluted basis as of the Fifth Amendment Additional Advance Date (or 2,267,145 shares of Common Stock as of the Closing Date).
On the Closing Date, the Company issued an aggregate of 429,537 of the Closing Date Warrants to the ABL Lenders. Upon approval by the Nasdaq of the Company’s listing application regarding the Warrant Shares, the Company will issue a further 429,967 of the Closing Date Warrants to the ABL Lenders. The remaining Closing Date Warrants will be issued upon receipt by the Company of the approval of its shareholders of the issuance of the Warrant Shares.
The Warrant Agreement provides that if the Company has not obtained the approval of its shareholders with respect to the transactions contemplated by the Warrant Agreement, then the Company may only issue, upon exercise of the Series F Warrants, a number of Warrant Shares which, when aggregated with any shares of Common Stock issued on or after the Closing Date and prior to such exercise date, would not exceed 859,504 shares of Common Stock (or approximately 19.99% of the outstanding Common Stock as of the Closing Date) (the “Issuable Maximum”).
Until such time as the Series F Warrants and the Warrant Shares issuable upon exercise of the Series F Warrants are registered under the Securities Act of 1933, as amended (the “Securities Act”), such warrants and shares will be subject to restrictions on transfer.